These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31239768)

  • 41. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis.
    Zhang CH; Xu GL; Jia WD; Ge YS; Li JS; Ma JL; Ren WH
    Int J Cancer; 2012 Jun; 130(11):2685-92. PubMed ID: 21780114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic implication of NQO1 overexpression in hepatocellular carcinoma.
    Lin L; Sun J; Tan Y; Li Z; Kong F; Shen Y; Liu C; Chen L
    Hum Pathol; 2017 Nov; 69():31-37. PubMed ID: 28964792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Investigation of the value of miR-21 in the diagnosis of early stage HCC and its prognosis: a meta-analysis.
    Yan SR; Liu ZJ; Yu S; Bao YX
    Genet Mol Res; 2015 Sep; 14(3):11573-86. PubMed ID: 26436398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modified Glasgow prognostic score might be a prognostic factor for hepatocellular carcinoma: a meta-analysis.
    Chen H; Hu N; Chang P; Kang T; Han S; Lu Y; Li M
    Panminerva Med; 2017 Dec; 59(4):302-307. PubMed ID: 28001023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma.
    Cha YL; Li PD; Yuan LJ; Zhang MY; Zhang YJ; Rao HL; Zhang HZ; Zheng XF; Wang HY
    PLoS One; 2015; 10(2):e0117493. PubMed ID: 25658620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis.
    Zhou Y; Wang XB; Qiu XP; Shuai Zhang ; Wang C; Zheng F
    Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):529-541. PubMed ID: 30143452
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study.
    Chen G; Dang YW; Luo DZ; Feng ZB; Tang XL
    Oncol Res; 2008; 17(4):183-9. PubMed ID: 18773863
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma.
    Li Y; Yu HP; Zhang P
    Hepatol Int; 2016 May; 10(3):488-92. PubMed ID: 26643668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic and clinicopathological value of Beclin-1 expression in hepatocellular carcinoma: a meta-analysis.
    Qin Z; Yu X; Lin M; Wu J; Ma S; Wang N
    World J Surg Oncol; 2018 Aug; 16(1):170. PubMed ID: 30107804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Caveolin-1, a Key Mediator Across Multiple Pathways in Glioblastoma and an Independent Negative Biomarker of Patient Survival.
    Moriconi C; Civita P; Neto C; Pilkington GJ; Gumbleton M
    Front Oncol; 2021; 11():701933. PubMed ID: 34490102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HCC in patients without cirrhosis: A review.
    Aryan M; Ruli T; Shoreibah M
    Clin Liver Dis (Hoboken); 2024; 23(1):e0224. PubMed ID: 38872781
    [No Abstract]   [Full Text] [Related]  

  • 53. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway.
    Zhao D; Yang Z; Chen C; Zhang Z; Yu Y; Li Z
    FEBS Open Bio; 2021 Nov; 11(11):3115-3125. PubMed ID: 34555268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and characterization of magnetic nanoparticles coated with polystyrene sulfonic acid for biomedical applications.
    Chen BW; He YC; Sung SY; Le TTH; Hsieh CL; Chen JY; Wei ZH; Yao DJ
    Sci Technol Adv Mater; 2020 Jul; 21(1):471-481. PubMed ID: 32939172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New relationship of E2F1 and BNIP3 with caveolin-1 in lung cancer-associated fibroblasts.
    Shen C; Chen X; Xiao K; Che G
    Thorac Cancer; 2020 Jun; 11(6):1369-1371. PubMed ID: 32212370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of caveolin-1 protein expression with hepatocellular carcinoma: a meta-analysis and literature review.
    Zhang Y; Fan W; Wu J; Dong J; Cui Z
    Cancer Manag Res; 2019; 11():5113-5122. PubMed ID: 31239768
    [No Abstract]   [Full Text] [Related]  

  • 57. Expression and significance of caveolin-1 in hepatitis B virus-associated hepatocellular carcinoma.
    Cheng H; Pan Y; Yao Y; Zhu Z; Chen J; Sun X; Qiu Y; Ding Y
    Exp Ther Med; 2017 Nov; 14(5):4356-4362. PubMed ID: 29067114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Caveolin enhances hepatocellular carcinoma cell metabolism, migration, and invasion in vitro via a hexokinase 2-dependent mechanism.
    Chai F; Li Y; Liu K; Li Q; Sun H
    J Cell Physiol; 2019 Feb; 234(2):1937-1946. PubMed ID: 30144070
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The contribution of caveolin-1 genotype and phenotype to hepatocellular carcinoma.
    Hsu CM; Yang MD; Tsai CW; Ho CY; Chang WS; Chang SC; Jeng LB; Tsai Y; Tsai FJ; Bau DT
    Anticancer Res; 2013 Feb; 33(2):671-7. PubMed ID: 23393366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis.
    Zhou L; Zhu Y
    Int J Surg; 2018 Aug; 56():274-280. PubMed ID: 29936198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.